Ironwood Pharmaceuticals (IRWD) : 8 analysts are covering Ironwood Pharmaceuticals (IRWD) and their average rating on the stock is 2, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Ironwood Pharmaceuticals (IRWD) : 8 Wall Street analysts covering Ironwood Pharmaceuticals (IRWD) believe that the average level the stock could reach for the short term is $15. The maximum price target given is $24 and the minimum target for short term is around $10, hence the standard deviation is calculated at $4.28.
Company shares have received an average consensus rating of Hold for the current week Ironwood Pharmaceuticals (NASDAQ:IRWD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $13.20 and $13.03 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $13.49. The buying momentum continued till the end and the stock did not give up its gains. It closed at $13.34, notching a gain of 1.21% for the day. The total traded volume was 977,050 . The stock had closed at $13.18 on the previous day.
In a related news, The director, of Ironwood Pharmaceuticals Inc, Olanoff Lawrence S had unloaded 2,200 shares at $12.92 per share in a transaction on June 3, 2016. The total value of transaction was $28,424. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.